Oncology (all articles) | Page 18 of 124 | Links Medicus Content Curation & Alerts in Medicine

Review | Advances in the diagnosis and early management of gestational trophoblastic disease

19 Jan, 2023 | 14:08h | UTC

Advances in the diagnosis and early management of gestational trophoblastic disease – BMJ Medicine

SR | Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation

19 Jan, 2023 | 14:09h | UTC

Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation – Cochrane Library

Summary: Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation – Cochrane Library

Post-trial follow-up | Efficacy and safety of first-line lorlatinib vs. crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer

19 Jan, 2023 | 13:49h | UTC

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)

Original Study: First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer – New England Journal of Medicine

Commentary on Twitter

NEW—Updated, long-term data from the CROWN study show durable benefit of lorlatinib vs crizotinib in pts w/ treatment-naive, ALK-positive #NSCLC

From Prof Benjamin Solomon & colleagues https://t.co/jfOEMRNEgl pic.twitter.com/SBaRCBEGIy

— The Lancet Respiratory Medicine (@LancetRespirMed) December 19, 2022

RCT | Nivolumab plus Ipilimumab vs. EXTREME regimen as first-line treatment for recurrent/metastatic head and neck cancer

19 Jan, 2023 | 13:41h | UTC

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651 – Journal of Clinical Oncology

Commentary: First-Line Nivolumab/Ipilimumab vs EXTREME Regimen in Recurrent or Metastatic Head and Neck Cancer – The ASCO Post

ACG Clinical Guideline | Diagnosis and management of gastrointestinal subepithelial lesions

18 Jan, 2023 | 14:39h | UTC

ACG Clinical Guideline: Diagnosis and Management of Gastrointestinal Subepithelial Lesions – The American Journal of Gastroenterology

Cohort Study | Brain cancer after radiation exposure from CT examinations of children and young adults

18 Jan, 2023 | 14:36h | UTC

Brain cancer after radiation exposure from CT examinations of children and young adults: results from the EPI-CT cohort study – The Lancet Oncology (link to abstract – $ for full-text)

Commentaries:

Large Multinational Study Shows Link Between CT Radiation Exposure and Brain Cancer in Children and Young Adults – Diagnostic Imaging

New cancer risk analysis prompts experts to call for ‘careful justification’ of pediatric head CTs – Health Imaging

CT brain cancer risk quantified for children and young adults – medwire News

Consensus Statement | Management of patients with advanced prostate cancer

18 Jan, 2023 | 14:26h | UTC

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022 – European Urology

SR | Pre‐emptive antifungal therapy vs. empirical antifungal therapy for febrile neutropenia in people with cancer

18 Jan, 2023 | 14:18h | UTC

Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer – Cochrane Library

Summary: Pre-emptive versus empirical antifungal therapy in people with cancer who have febrile neutropenia – Cochrane Library

Review | Role of immunotherapy in breast cancer

18 Jan, 2023 | 14:03h | UTC

Role of Immunotherapy in Breast Cancer – JCO Oncology Practice

A deep learning model may predict future lung cancer risk from a single low-dose chest CT

18 Jan, 2023 | 14:00h | UTC

Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography – Journal of Clinical Oncology

News Release: Artificial intelligence tool developed to predict risk of lung cancer – Massachusetts General Hospital

Commentary: AI tool predicts lung cancer without radiologists or clinical histories – Health Imaging

Cohort Study | Cognitive and behavioral development of 9-year-old children after maternal cancer during pregnancy

18 Jan, 2023 | 13:58h | UTC

Cognitive and Behavioral Development of 9-Year-Old Children After Maternal Cancer During Pregnancy: A Prospective Multicenter Cohort Study – Journal of Clinical Oncology

Cancer statistics in the US, 2023

17 Jan, 2023 | 13:24h | UTC

Cancer statistics, 2023 – CA: A Cancer Journal for Clinicians

News Release: American Cancer Society’s annual report on cancer facts and trends released – News Medical / American Cancer Society

Commentaries:

Incidence Drops for Cervical Cancer But Rises for Prostate Cancer – American Cancer Society

American Cancer Society’s Cancer Statistics 2023 Report Released: Shows Continued Declines in Cancer Mortality, Persistent Racial Disparities, and More – The ASCO Post

US cancer death rate falls 33% since 1991, partly due to advances in treatment, early detection and less smoking, report says – CNN

RCT | Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after auto-SCT in patients with multiple myeloma

17 Jan, 2023 | 13:11h | UTC

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Triple-drug therapy for post-transplant management of multiple myeloma – University of Chicago Medical Center

M-A | Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival?

17 Jan, 2023 | 13:07h | UTC

Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials – ESMO Open

ESMO Guideline | Venous thromboembolism in cancer patients

15 Jan, 2023 | 20:21h | UTC

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline – Annals of Oncology

Cancer-associated venous thromboembolism – Nature Reviews Disease Primers

Infographic: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers

NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.

ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer

Review: venous and arterial thromboembolism in patients with cancer.

M-A: Extended thromboprophylaxis after hospital discharge for medically ill patients with cancer – Extended thromboprophylaxis is not associated with a reduced rate of venous thromboembolic events and is associated with increased risk of hemorrhage

Systematic review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

Consensus Paper | Revision of classification system for reporting on skin biopsies of melanocytic lesions

15 Jan, 2023 | 20:17h | UTC

Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement – JAMA Network Open

Commentaries:

Classification system for reporting on skin biopsies of melanocytic lesions – University of California – Los Angeles Health Sciences

MPATH-Dx Version 2.0 Simplifies Classification of Melanoma – HealthDay

Commentary on Twitter

American and international #dermatopathologists revise Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis schema. MPATH-Dx V2.0 improves standardized diagnostic reporting and patient management of #melanoma. https://t.co/G0fluzq5fs

— JAMA Network Open (@JAMANetworkOpen) January 12, 2023

Synopsis | Endocrine Society hypercalcemia of malignancy guidelines

15 Jan, 2023 | 22:13h | UTC

Endocrine Society Hypercalcemia of Malignancy Guidelines – JAMA Oncology (free for a limited period)

Original article: Guideline | Treatment of hypercalcemia of malignancy in adults

RCT | MRI–guided vs. CT–guided stereotactic body radiotherapy for prostate cancer

15 Jan, 2023 | 20:05h | UTC

Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial – JAMA Oncology

News Release: MRI-guided radiotherapy produces fewer side effects and better quality of life for patients with localized prostate cancer – University of California

Commentary from the author on Twitter (thread – click for more)

Pleased to share the primary endpoint results of the randomized phase III MIRAGE trial evaluating whether aggressive margin reduction with MRI-guidance leads to reduced toxicity in the context of prostate SBRT, out today in @JAMAOncology https://t.co/5ZKElUR4uk (1/n)

— Amar Kishan (@AmarUKishan) January 12, 2023

RCT | Cosmetic results and side effects of accelerated partial-breast irradiation vs. whole-breast irradiation for low-risk invasive carcinoma of the breast

15 Jan, 2023 | 19:53h | UTC

Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary from the author on Twitter

5yr results of the phase 3 #IRMAtrial: EBRT #APBI b.i.d. associated with slightly increased rate of moderate soft tissue and bone toxicity and a slightly inferior cosmesis, though overall toxicity was in an acceptable range @JCO_ASCO #BCSM @OncoAlert https://t.co/8LHE2ut3t2

— Bruno Meduri (@brunomeduri) January 9, 2023